» Articles » PMID: 29680221

Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention: An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients

Abstract

Objectives: This study sought to investigate the impact of nonemergent, uncomplicated target lesion revascularization (TLR) on the risk of long-term mortality after percutaneous coronary intervention (PCI).

Background: Restenosis requiring TLR after PCI is generally considered a benign event.

Methods: The study pooled patient-level data from 21 randomized trials. Subjects dying the same day as or the day after the TLR procedure as well as those with myocardial infarction (MI) the day before, the same day as or the day after TLR were excluded. The primary endpoint of the study was all-cause mortality.

Results: The dataset included 32,524 patients who were stratified according to whether repeat TLR was performed during follow-up. During a median follow-up of 37 months, 2,330 (7.2%) patients underwent a nonemergent, uncomplicated TLR procedure. After adjusting for potential confounders, TLR was an independent predictor of mortality (hazard ratio: 1.23, 95% confidence interval: 1.04 to 1.45; p = 0.02). Patients undergoing nonemergent, uncomplicated TLR had significantly higher rates of non-procedure-related MI compared with those without TVR. Among patients undergoing elective TLR, MI occurring after TLR was an independent predictor of mortality (hazard ratio: 3.82; 95% confidence interval: 2.44 to 5.99; p < 0.0001).

Conclusions: Nonemergent, uncomplicated TLR after PCI is an independent predictor of long-term mortality, an association in part explained by higher rates of MI occurring after TLR. Efforts aimed at reducing TLR risk may translate into prognostic benefits including reduced rates of MI and survival.

Citing Articles

Elderly patients treated with Onyx versus Orsiro drug-eluting coronary stents in a randomized clinical trial with long-term follow-up.

van Vliet D, Ploumen E, Pinxterhuis T, Doggen C, Aminian A, Schotborgh C Clin Res Cardiol. 2025; .

PMID: 40035811 DOI: 10.1007/s00392-025-02622-7.


Sex and age-specific 10-year mortality after coronary stenting: an analysis of two randomized trials.

Pinxterhuis T, Ploumen E, Doggen C, van Vliet D, Kok M, Zocca P Eur Heart J Open. 2025; 5(1):oeaf006.

PMID: 39959922 PMC: 11829202. DOI: 10.1093/ehjopen/oeaf006.


Recent Advances in the Treatment of Coronary In-Stent Restenosis.

Sartore L, Gitto M, Oliva A, Kakizaki R, Mehran R, Raber L Rev Cardiovasc Med. 2025; 25(12):433.

PMID: 39742224 PMC: 11683712. DOI: 10.31083/j.rcm2512433.


Long-term outcomes following ultrathin vs thin-strut drug-eluting stents for percutaneous coronary intervention: an updated systematic review and meta-analysis of randomized control trials.

Yasmin F, Zaidi S, Moeed A, Khan M, Ali E, Asghar M Am J Cardiovasc Dis. 2024; 14(5):267-280.

PMID: 39583995 PMC: 11578867. DOI: 10.62347/UCLC9729.


Treatment of in-stent restenosis with ultrathin-strut versus thin-strut drug-eluting stents or drug-eluting balloons: a multicentre registry.

De Filippo O, Wanha W, Sanavia T, Januszek R, Giacobbe F, Campo G EuroIntervention. 2024; 20(21):e1340-e1354.

PMID: 39492702 PMC: 11525456. DOI: 10.4244/EIJ-D-24-00491.